Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. Veracyte, Inc. sells its products through product specialists, institutional managers, account managers, and medical science specialists. Veracyte, Inc. has research collaboration agreement with Loxo Oncology to develop medicines for patients with genetically defined cancers. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone650-243-6300
Debt
Current Ratio9.14
Quick Ratio8.81
Price-To-Earnings
Sales & Book Value
Annual Sales$71.95 million
Price / Sales8.84
Price / Cash FlowN/A
Price / Book14.39
Profitability
Net Income$-31,000,000.00
Net Margins-33.00%
Return on Assets-33.89%
Miscellaneous
Employees246
OptionableOptionable
Veracyte (NASDAQ:VCYT) Frequently Asked Questions
What is Veracyte's stock symbol?
Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
How were Veracyte's earnings last quarter?
Veracyte Inc (NASDAQ:VCYT) posted its quarterly earnings results on Monday, October, 29th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.25) by $0.13. The biotechnology company had revenue of $23.47 million for the quarter, compared to the consensus estimate of $21.52 million. Veracyte had a negative net margin of 33.00% and a negative return on equity of 65.73%. View Veracyte's Earnings History.
When is Veracyte's next earnings date?
What guidance has Veracyte issued on next quarter's earnings?
Veracyte updated its FY 2018 earnings guidance on Monday, October, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $90-91 million, compared to the consensus revenue estimate of $88.09 million.
What price target have analysts set for VCYT?
4 brokers have issued 12-month target prices for Veracyte's stock. Their forecasts range from $11.00 to $17.00. On average, they expect Veracyte's share price to reach $13.4333 in the next year. This suggests that the stock has a possible downside of 14.4%. View Analyst Price Targets for Veracyte.
What is the consensus analysts' recommendation for Veracyte?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.
Has Veracyte been receiving favorable news coverage?
Media headlines about VCYT stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Veracyte earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the next few days.
Are investors shorting Veracyte?
Veracyte saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,150,033 shares, an increase of 58.1% from the December 14th total of 1,359,751 shares. Based on an average daily trading volume, of 311,061 shares, the days-to-cover ratio is currently 6.9 days. Currently, 7.0% of the shares of the company are sold short. View Veracyte's Current Options Chain.
Who are some of Veracyte's key competitors?
Some companies that are related to Veracyte include Genomic Health (GHDX), InVitae (NVTA), CareDx (CDNA), Natera (NTRA), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), Fulgent Genetics (FLGT), PotNetwork (POTN), First Choice Healthcare Solutions (FCHS), OpGen (OPGN), CBA Florida (CBAI) and Cancer Genetics (CGIX).
Who are Veracyte's key executives?
Veracyte's management team includes the folowing people:
- Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)
- Mr. Christopher M. Hall, Pres & COO (Age 50)
- Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)
- Dr. Giulia C. Kennedy Ph.D., Chief Scientific Officer & Head of Scientific, Clinical and Medical Affairs Department (Age 60)
- Mr. Ashish Kheterpal, Chief Information Officer
How do I buy shares of Veracyte?
Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veracyte's stock price today?
One share of VCYT stock can currently be purchased for approximately $15.69.
How big of a company is Veracyte?
Veracyte has a market capitalization of $651.05 million and generates $71.95 million in revenue each year. The biotechnology company earns $-31,000,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Veracyte employs 246 workers across the globe.
What is Veracyte's official website?
How can I contact Veracyte?
Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]
MarketBeat Community Rating for Veracyte (NASDAQ VCYT)
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
